Productivity shortfalls in drug discovery: Contributions from the preclinical sciences?

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 3-8

  Williams, Michael ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 220; ATROPINE; CODEINE; ERLOTINIB; IMATINIB; MORPHINE; OXYBUTYNIN; OXYCODONE; PHOSPHOTRANSFERASE INHIBITOR; PLX 4032; SCOPOLAMINE; SORAFENIB; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE MAPPING; GENOME; HUMAN; MELANOMA; NEOPLASM; PRIORITY JOURNAL; PRODUCTIVITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOTECHNOLOGY; DRUG APPROVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EFFICIENCY, ORGANIZATIONAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78650798983     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.171751     Document Type: Review

References (51)

1. Austin CP, Brady LS, Insel TR, and Collins FS (2004) NIH Molecular Libraries Initiative. Science 306:1138-1139.
2. Barras R (1986) Towards a theory of innovation in services. Research Policy 15:161-173.
3. Boyer PJ (2010) The covenant. The New Yorker, September 16, 2010. Available at: http://www.newyorker.com/reporting/2010/09/06/100906fa-fact-boyer.
4. rd ed, pp 203-219, Wadsworth, Belmont, CA.
5. Carmichael M and Begley S (2010) Desperately seeking cures. Newsweek, May 15, 2010, http://www.newsweek.com/2010/05/15/desperately-seeking-cures.html.
6. Carpenter DP (2010) Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, Princeton University Press, Princeton, NJ.
7. Carr G (2010) Biology 2.0. A special report on the human genome. Economist, June 19, 2010.
8. Collins FS, Green ED, Guttmacher AE, Guyer MS, and US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature 422:835-847.
9. Corbett AD, Henderson G, McKnight AT, and Paterson SJ (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147:S153-S162.
10. Cuatrecasas P (2006) Drug discovery in jeopardy. J Clin Invest 116:2837-2842.
11. Douglas FL, Narayanan VK, Mitchell L, and Litan RE (2010) The case for entrepreneurship in R&D in the pharmaceutical industry. Nat Rev Drug Discov 9:683-689.
12. Enna SJ and Williams M (2009a) Challenges in the search for drugs to treat central nervous system disorders. J Pharmacol Exp Ther 329:404-411.
13. Enna SJ and Williams M (2009b) Defining the role of pharmacology in the emerging world of translational research. Adv Pharmacol 57:1-30.
14. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336.
15. Fryburg DA (2010) Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can impact productivity. Drug Discov Today doi:10.1016/j.drudis.2010. 06.010.
16. Goodwin F (2010) Fortune's Fool, Simon and Schuster, New York.
17. Horrobin DF (2003) Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2:151-154.
18. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, and Juan HF (2008) Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res 7:1433-1444.
19. International Human Genome Sequencing Consortium. (2004) Finishing the euchromatic sequence of the human genome. Nature 431:931-945.
20. Kaiser J (2008) Molecular biology. Industrial-style screening meets academic biology. Science 321:764-766.
21. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
22. Karginov AV, Ding F, Kota P, Dokholyan NV, and Hahn KM (2010) Engineered allosteric activation of kinases in living cells. Nat Biotechnol 28:743-747.
23. Kenakin TP (2009) A Pharmacology Primer, 3rd ed, pp. xv, Academic Press, Burlington, MA.
24. Kubinyi H (2003) Drug research: myths, hype and reality. Nat Rev Drug Discov 2:665-668.
25. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26. (Pubitemid 33653411)
26. Maddox J (1992) Is molecular biology yet a science? Nature 355:201.
27. Manning G, Whyte DB, Martinez R, Hunter T, and Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934.
28. Marino MJ, Knutsen LJ, and Williams M (2008) Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J Med Chem 51:1077-1107.
29. Mendoza MC and Lindenmayer JP (2009) N-desmethylclozapine: is there evidence for its antipsychotic potential? Clin Neuropharmacol 32:154-157.
30. Merck GW (1950) Address to the Medical College of Virginia, Richmond, VA, Dec. 1, 1950. In Collins JC and Porras JI (2002) Built to Last, p 49, Harper Business Essentials, New York.
31. Miller G (2010) Is pharma running out of brainy ideas? Science 329:502-504.
32. Mirza NR, Peters D, and Sparks RG (2003) Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9:159-186.
33. Morgan TM, Krumholz HM, Lifton RP, and Spertus JA (2007) Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 297:1551-1561.
34. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959-968.
35. O'Sullivan D (2002) Framework for managing development in the networked organisation. Computers Industr 47:77-88.
36. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, and Ridker PM (2010) Association between a literature-based genetic risk score and cardiovascular events in women. JAMA 303:631-637.
37. Pisano G (2006) Science Business: The Promise, the Reality, and the Future of Biotech, Harvard Business School Press, Boston.
38. Prud'homme A (2004) The Cell Game. Sam Waksal's Fast Money and False Promises - and the Fate of ImClone's Cancer Drug, Harper Collins, New York.
39. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
40. Sams-Dodd F (2005) Target-based drug discovery: is something wrong? Drug Discov Today 10:139-147.
41. Shaywitz D and Taleb N (2008) Drug research needs serendipity. Financial Times, July 29, 2008. http://www.ft.com/cms/s/0/b735787c-5d9b-11dd-8129- 000077b07658.html. Accessed 7/4/10.
42. Tsai J, Lee JT, Wang W, Zhang J, Hanna Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-3046.
43. Ullman F and Boutellier R (2008) Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discov Today 13:997-1001.
44. Uitdehaag JC (2007) Where is the optimism? Warrior teachings to regain the drug discovery spirit. Drug Discov Today 12:105-107.
45. Wehling M (2009) Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 8:541-546.
46. Weisbach JA and Moos HW (1995) Diagnosing the decline of major pharmaceutical research laboratories: a prescription for drug companies. Drug Dev Res 34:243-259.
47. Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, Ray A, Moreno D, Kung AL, Gray N, and Griffin JD (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia 24:1375-1378.
48. Wess J, Eglen RM, and Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733.
49. Williams M (2005) Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem Pharmacol 70:1707-1716.
50. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, et al. (2009) AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114:2984-2992.
51. Zhang J, Yang PL, and Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39.